ES2058180T3 - T-pa mutante con reemplazo de kringle. - Google Patents

T-pa mutante con reemplazo de kringle.

Info

Publication number
ES2058180T3
ES2058180T3 ES88108949T ES88108949T ES2058180T3 ES 2058180 T3 ES2058180 T3 ES 2058180T3 ES 88108949 T ES88108949 T ES 88108949T ES 88108949 T ES88108949 T ES 88108949T ES 2058180 T3 ES2058180 T3 ES 2058180T3
Authority
ES
Spain
Prior art keywords
analogs
kringle
fibrin
native
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88108949T
Other languages
English (en)
Inventor
Eileen R Mulvihill
Bjorn A Nexo
Shinji Yoshitake
Yasunori Ikeda
Suguru Suzuki
Akira Hashimoto
Teruaki Yuzuriha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Eisai Co Ltd
Zymogenetics Inc
Original Assignee
Novo Nordisk AS
Eisai Co Ltd
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Eisai Co Ltd, Zymogenetics Inc filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2058180T3 publication Critical patent/ES2058180T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

LA INVENCION SE REFIERE A ANALOGOS DE T-PA QUE PRESENTAN MAYOR ESPECIFICIDAD PARA LA FIBRINA QUE EL T-PA NATURAL. LOS ANALOGOS TIENEN EL DOMINIO K1 DEL T-PA NATURAL REEMPLAZADO CON OTRO DOMINIO "KRINGLE" QUE MEDIATIZA LA UNION DEL ANALOGO A LA FIBRINA. EL "KRINGLE" CONTIENE SEIS RESTOS DE CISTEINA. LOS ANALOGOS DE T-PA PUEDEN INCLUIR ADEMAS UNA VARIEDAD DE SUSTITUCIONES Y MODIFICACIONES. TAMBIEN SE REFIERE LA INVENCION A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UNO O MAS ANALOGOS DE T-PA JUNTO A UN VEHICULO O DILUYENTE FARMACEUTICAMENTE ACEPTABLE.
ES88108949T 1987-06-04 1988-06-03 T-pa mutante con reemplazo de kringle. Expired - Lifetime ES2058180T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5821787A 1987-06-04 1987-06-04

Publications (1)

Publication Number Publication Date
ES2058180T3 true ES2058180T3 (es) 1994-11-01

Family

ID=22015426

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88108949T Expired - Lifetime ES2058180T3 (es) 1987-06-04 1988-06-03 T-pa mutante con reemplazo de kringle.

Country Status (14)

Country Link
EP (1) EP0293934B1 (es)
JP (1) JPS6485078A (es)
KR (1) KR970005251B1 (es)
AT (1) ATE110772T1 (es)
AU (1) AU617323B2 (es)
CA (1) CA1341447C (es)
DE (1) DE3851259T2 (es)
DK (1) DK302288A (es)
ES (1) ES2058180T3 (es)
FI (1) FI882628A (es)
IE (1) IE64782B1 (es)
NO (1) NO179754C (es)
NZ (1) NZ224915A (es)
ZA (1) ZA883958B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187098A (en) * 1984-03-02 1993-02-16 Board Of Regents Of The University Of Oklahoma DNA encoding hybrid streptokinases with plasminogen fibrin binding domains
US5714372A (en) * 1985-04-22 1998-02-03 Genentech, Inc. Tissue plasminogen activator variants
US5756093A (en) * 1985-04-22 1998-05-26 Genentech, Inc. Tissue plasminogen activator variants
US5736134A (en) * 1985-04-22 1998-04-07 Genentech, In.C Tissue plasminogen activator variants
US5302390A (en) * 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
DE3836200A1 (de) * 1988-10-24 1990-04-26 Boehringer Mannheim Gmbh Domaenenduplikations-muteine des gewebsplasminogen-aktivators (t-pa)
GB8901422D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co New tissue plasminogen activator
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5272076A (en) * 1991-06-13 1993-12-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
JP3112480B2 (ja) * 1991-12-16 2000-11-27 ジェネンテク，インコーポレイテッド 新規な組織プラスミノーゲン活性化因子変異体
DE10199044I2 (de) * 1992-06-03 2006-02-09 Genentech Inc Varianten des Gewebeplasminogenaktivators mit verbesserter Therapeutischer wirkung
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125254A1 (en) * 1982-10-28 1984-11-21 Beecham Group Plc Enzyme derivatives and their use in the treatment of thrombosis
DK149786A (da) * 1985-04-04 1986-10-04 Beecham Group Plc Proteolytisk enzym
FR2581652B1 (fr) * 1985-04-22 1989-12-22 Genentech Inc Nouveaux mutants de l'activateur tissulaire du plasminogene humain
IE81073B1 (en) * 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
PT84588B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
DE3643158A1 (de) * 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
ES2069536T3 (es) * 1987-06-04 1995-05-16 Zymogenetics Inc Analogos del activador del plasminogeno tisular que tienen dominios modificados del factor de crecimiento.

Also Published As

Publication number Publication date
DE3851259T2 (de) 1994-12-15
AU617323B2 (en) 1991-11-28
IE881681L (en) 1988-12-04
IE64782B1 (en) 1995-09-06
DK302288A (da) 1989-02-03
NO882453L (no) 1988-12-05
FI882628A (fi) 1988-12-05
JPS6485078A (en) 1989-03-30
AU1741088A (en) 1988-12-08
JPH0448433B2 (es) 1992-08-06
KR970005251B1 (ko) 1997-04-14
ATE110772T1 (de) 1994-09-15
KR890000665A (ko) 1989-03-16
NO179754B (no) 1996-09-02
EP0293934A1 (en) 1988-12-07
NO179754C (no) 1996-12-11
DK302288D0 (da) 1988-06-03
FI882628A0 (fi) 1988-06-03
NZ224915A (en) 1989-12-21
DE3851259D1 (de) 1994-10-06
EP0293934B1 (en) 1994-08-31
CA1341447C (en) 2003-11-18
NO882453D0 (no) 1988-06-03
ZA883958B (en) 1989-07-26

Similar Documents

Publication Publication Date Title
ES2058180T3 (es) T-pa mutante con reemplazo de kringle.
ES2091224T3 (es) Subtilisinas con mutaciones multiples.
DE3686410D1 (de) Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens.
JPS6485079A (en) Tissue plasminogen activating factor analog having improved proliferating factor domain
ATE103178T1 (de) T-pa pro stabilisierung.
AU6205390A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 293934

Country of ref document: ES